JP2017527590A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527590A5
JP2017527590A5 JP2017514411A JP2017514411A JP2017527590A5 JP 2017527590 A5 JP2017527590 A5 JP 2017527590A5 JP 2017514411 A JP2017514411 A JP 2017514411A JP 2017514411 A JP2017514411 A JP 2017514411A JP 2017527590 A5 JP2017527590 A5 JP 2017527590A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017514411A
Other languages
English (en)
Japanese (ja)
Other versions
JP6660060B2 (ja
JP2017527590A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/050289 external-priority patent/WO2016044342A1/en
Publication of JP2017527590A publication Critical patent/JP2017527590A/ja
Publication of JP2017527590A5 publication Critical patent/JP2017527590A5/ja
Application granted granted Critical
Publication of JP6660060B2 publication Critical patent/JP6660060B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017514411A 2014-09-16 2015-09-15 ヒストンデメチラーゼ阻害剤 Expired - Fee Related JP6660060B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051268P 2014-09-16 2014-09-16
US62/051,268 2014-09-16
PCT/US2015/050289 WO2016044342A1 (en) 2014-09-16 2015-09-15 Histone demethylase inhibitors

Publications (3)

Publication Number Publication Date
JP2017527590A JP2017527590A (ja) 2017-09-21
JP2017527590A5 true JP2017527590A5 (enExample) 2018-10-25
JP6660060B2 JP6660060B2 (ja) 2020-03-04

Family

ID=55533770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017514411A Expired - Fee Related JP6660060B2 (ja) 2014-09-16 2015-09-15 ヒストンデメチラーゼ阻害剤

Country Status (17)

Country Link
US (2) US9676770B2 (enExample)
EP (1) EP3193881B1 (enExample)
JP (1) JP6660060B2 (enExample)
KR (1) KR20170048590A (enExample)
CN (1) CN107073006A (enExample)
AU (1) AU2015317904A1 (enExample)
BR (1) BR112017005128A2 (enExample)
CA (1) CA2961525A1 (enExample)
CL (1) CL2017000643A1 (enExample)
CO (1) CO2017002772A2 (enExample)
EA (1) EA201790502A1 (enExample)
EC (1) ECSP17020172A (enExample)
ES (1) ES2911292T3 (enExample)
IL (1) IL251103A0 (enExample)
MX (1) MX2017003464A (enExample)
SG (1) SG11201702108PA (enExample)
WO (1) WO2016044342A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2731773T3 (es) 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2017003464A (es) * 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
SI3371190T1 (sl) 2015-11-06 2022-08-31 Incyte Corporation Heterociklične spojine kot inhibitorji PI3K gama
WO2017120194A1 (en) * 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
WO2017161033A1 (en) * 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
SI3697789T1 (sl) 2017-10-18 2022-04-29 Incyte Corporation Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN111116571B (zh) * 2019-12-27 2022-07-12 吉首大学 含恶唑及三唑双杂环的化合物及其制备与应用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1058549A4 (en) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
MXPA03003599A (es) 2000-10-26 2003-08-01 Tularik Inc Agentes antiinflamatorios.
GB0217780D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2632444A1 (en) 2005-12-19 2007-06-28 Boehringer Ingelheim International Gmbh Use of aminoalcohol derivatives for the treatment of overactive bladder
CA2701124A1 (en) 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
CA2778886C (en) 2009-11-10 2014-01-07 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
EP3763367A1 (en) * 2012-12-06 2021-01-13 Celgene Quanticel Research, Inc. Pyridine-pyrazole derivatives as histone demethylase inhibitors
ES2731773T3 (es) * 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9896436B2 (en) * 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.

Similar Documents

Publication Publication Date Title
JP2017527590A5 (enExample)
JP2016514159A5 (enExample)
JP2016501882A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2016503799A5 (enExample)
PH12020552187A1 (en) Pcsk9 antagonist compounds
JP2017523152A5 (enExample)
JP2016531126A5 (enExample)
JP2016518328A5 (enExample)
JP2016506935A5 (enExample)
JP2016503809A5 (enExample)
JP2016503793A5 (enExample)
JP2016501250A5 (enExample)
JP2013537203A5 (enExample)
JP2017514910A5 (enExample)
JP2016528273A5 (enExample)
JP2016529319A5 (enExample)
JP2015522589A5 (enExample)
JP2014513051A5 (enExample)
RU2017121002A (ru) Ингибиторы CD38 и способы лечения
JP2016529315A5 (enExample)
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
JP2016530242A5 (enExample)
JP2017537937A5 (enExample)
JP2016510719A5 (enExample)